

# The beneficial effect of oral Cr supplementation in an early childhood rat model of chronic hepatic encephalopathy: *in vivo* longitudinal <sup>1</sup>H and <sup>31</sup>P magnetic resonance spectroscopy study.


D. Simicic<sup>1,2</sup> PhD, O. Braissant<sup>3</sup> PhD, K. Pierzchala<sup>1,2</sup> PhD, S. Mitrea<sup>1,2</sup>, D. Sessa<sup>4</sup>, V. McLin<sup>4</sup> MD-PhD, C. Cudalbu<sup>1,2</sup> PhD

<sup>1</sup>CIBM Center for Biomedical Imaging, Lausanne, Switzerland, <sup>2</sup>Animal Imaging and Technology, EPFL, Lausanne, Switzerland, <sup>3</sup>Service of Clinical Chemistry, University of Lausanne and University Hospital of Lausanne, Switzerland, <sup>4</sup>Swiss Center for Liver Disease in Children, University Hospitals Geneva, Switzerland

## BACKGROUND

- Type C hepatic encephalopathy (C HE) is a complication of chronic liver disease (CLD).

- Children are more affected by CLD than adult patients<sup>1</sup>.
- The bile duct ligated rat (BDL) is a model of CLD - induced CHE validated in the adult and developing brain<sup>2,3</sup>.
- Rats having acquired CLD as pups display more profound neurometabolic disturbances than adults<sup>3</sup>. Cr-treatment showed a positive effect in young (P21) BDL-rats resulting in less pronounced metabolic changes (smaller Gln increase and PCr decrease)<sup>4</sup>.



## AIMS


→ Test if Cr supplementation dampens the neurometabolic changes observed in CHE in a longitudinal model of CLD acquired in early childhood (P15).

**HYPOTHESIS:** methods maintaining Cr concentration in type C HE may have potentially far-reaching clinical implications


## METHODS

- BDL and sham surgeries were performed on male Wistar rats at P15.

Rats from the treated group received **high Cr supplemented diet** with a concentration of **40g/kg**.




**MRS experiments:** 9.4T system (Varian / MagnexScientific) + home-built coil (quadrature <sup>1</sup>H-loops single <sup>31</sup>P-loop).



- <sup>1</sup>H-MRS spectra - hippocampus (2 x 2.8 x 2 mm<sup>3</sup>), SPECIAL<sup>5</sup> sequence (TE=2.8 ms) → quantification LCModel.
- <sup>31</sup>P-MRS spectra → non-selective AHP pulse for excitation, localized by OVS(x,z) + 1D-ISIS(y) in VOI = 5 x 9 x 9 mm<sup>3</sup>.
- <sup>31</sup>P-MR spectra → quantified using AMARES(jMRUI)<sup>6</sup>, normalized using PCr concentration from <sup>1</sup>H-MRS acquired in VOI = 4 x 7.5 x 6.5 mm<sup>3</sup> centered in <sup>31</sup>P-VOI.

## RESULTS


### <sup>1</sup>H-MRS



- Cr-treatment seemed to restore the decrease in Cr and tCr → higher Cr in BDL+Cr (+13% at week 6).


- Treatment seems to have a positive effect on other osmolytes (Ins, Tau and tCho) → less significant decrease in BDL+Cr

- Decrease of ascorbate is a hallmark of HE → Cr-treatment restored Asc in BDL rats emphasizing the antioxidant role of Cr.




## RESULTS

### <sup>31</sup>P-MRS



- PCr concentration at week4 was stable for BDL+Cr compared to BDL which had a significant decrease.
- BDL+Cr rats have a more stable tNAD pool.
- For non-treated BDL higher variations in tNAD → a more unstable redox state indicating an increased oxidative stress.



## CONCLUSION

- Our preliminary results showed an improved neurometabolic profile due to Cr supplementation accentuating the antioxidant role of Cr. BDL+Cr rats have a more stable tNAD pool.
- The positive effect on Asc and other osmolytes marks the need for combinatorial treatments in C HE.
- Additional studies are required to investigate if these differences due to Cr supplementation translate also into different neurological outcome.

## REFERENCES

- (1) Cagnon et al. *Brain Res Rev* (2007); Nicholas et al. *J Pediatr.* (2014); (2) Braissant et al. *J Hepatol.* (2019); (3) Rackayova et al. *Sci Rep.* (2020); (4) Rackayova et al. *ISMRM* (2017); (5) Mlynarik et al. *Mag Reson Med* (2000); (6) Vanhamme et al. 1997